Daliresp

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Roflumilast (Daliresp®, Daxas®) is a selective phosphodiesterase 4 (PDE4) inhibitor that decreases systemic and pulmonary… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
2014
2014
Roflumilast therapy has a limited role in patients with severe COPD, and no role in patients with mild to moderate COPD. It will… (More)
Is this relevant?
2013
2013
Objective To identify the structure of the new drug daliresp. Methods The structure of daliresp w as identified by UV,IR,MS,1H… (More)
Is this relevant?
2013
2013
APIXABAN (ELIQUIS®) FOR ORAL ANTICOAGULATION IN NONVALVULAR ATRIAL FIBRILLATION hronic obstructive pulmonary disease (COPD) is a… (More)
  • table 1
  • table 1
  • table 4
Is this relevant?
Review
2013
Review
2013
PURPOSE The pharmacology, pharmacokinetics, efficacy, and safety of roflumilast-the first in a new class of agents for managing… (More)
Is this relevant?
2012
2012
  • Jordan Baye
  • P & T : a peer-reviewed journal for formulary…
  • 2012
Chronic obstructive pulmonary disease (COPD) is characterized by a gradual and progressive loss of lung function. The consensus… (More)
Is this relevant?
2012
2012
is substantial. Quality of life, morbidity, and mortality are all negatively affected by the disease. In the National Health and… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2011
2011
  • The Medical letter on drugs and therapeutics
  • 2011
 
Is this relevant?
Review
2011
Review
2011
Roflumilast (Daxas® [EU], Daliresp® [USA]) is the first phosphodiesterase 4 inhibitor approved in Europe to be used in severe… (More)
  • table 1
Is this relevant?
2011
2011
roflumilast Chronic obstructive pulmonary disease (COPD) is a progressive, irreversible lung disease that is often associated… (More)
Is this relevant?